362 related articles for article (PubMed ID: 34777255)
1. Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Hirsova P; Bamidele AO; Wang H; Povero D; Revelo XS
Front Endocrinol (Lausanne); 2021; 12():760860. PubMed ID: 34777255
[TBL] [Abstract][Full Text] [Related]
2. Adaptive immunity: an emerging player in the progression of NAFLD.
Sutti S; Albano E
Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):81-92. PubMed ID: 31605031
[TBL] [Abstract][Full Text] [Related]
3. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma.
Koo SY; Park EJ; Lee CW
Exp Mol Med; 2020 Aug; 52(8):1209-1219. PubMed ID: 32770081
[TBL] [Abstract][Full Text] [Related]
4. Crucial role of T cells in NAFLD-related disease: A review and prospect.
Mao T; Yang R; Luo Y; He K
Front Endocrinol (Lausanne); 2022; 13():1051076. PubMed ID: 36457551
[TBL] [Abstract][Full Text] [Related]
5. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
6. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
7. Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis.
Chen Y; Tian Z
Front Immunol; 2020; 11():1500. PubMed ID: 32765518
[TBL] [Abstract][Full Text] [Related]
8. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
9. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.
Oniciu DC; Hashiguchi T; Shibazaki Y; Bisgaier CL
PLoS One; 2018; 13(5):e0194568. PubMed ID: 29847555
[TBL] [Abstract][Full Text] [Related]
10. State of CD8
Zhong X; Lv M; Ma M; Huang Q; Hu R; Li J; Yi J; Sun J; Zhou X
Biomed Pharmacother; 2023 Sep; 165():115131. PubMed ID: 37429231
[TBL] [Abstract][Full Text] [Related]
11. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.
Zeng F; Zhang Y; Han X; Zeng M; Gao Y; Weng J
Front Immunol; 2020; 11():609900. PubMed ID: 33574818
[TBL] [Abstract][Full Text] [Related]
12. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Pfister D; Núñez NG; Pinyol R; Govaere O; Pinter M; Szydlowska M; Gupta R; Qiu M; Deczkowska A; Weiner A; Müller F; Sinha A; Friebel E; Engleitner T; Lenggenhager D; Moncsek A; Heide D; Stirm K; Kosla J; Kotsiliti E; Leone V; Dudek M; Yousuf S; Inverso D; Singh I; Teijeiro A; Castet F; Montironi C; Haber PK; Tiniakos D; Bedossa P; Cockell S; Younes R; Vacca M; Marra F; Schattenberg JM; Allison M; Bugianesi E; Ratziu V; Pressiani T; D'Alessio A; Personeni N; Rimassa L; Daly AK; Scheiner B; Pomej K; Kirstein MM; Vogel A; Peck-Radosavljevic M; Hucke F; Finkelmeier F; Waidmann O; Trojan J; Schulze K; Wege H; Koch S; Weinmann A; Bueter M; Rössler F; Siebenhüner A; De Dosso S; Mallm JP; Umansky V; Jugold M; Luedde T; Schietinger A; Schirmacher P; Emu B; Augustin HG; Billeter A; Müller-Stich B; Kikuchi H; Duda DG; Kütting F; Waldschmidt DT; Ebert MP; Rahbari N; Mei HE; Schulz AR; Ringelhan M; Malek N; Spahn S; Bitzer M; Ruiz de Galarreta M; Lujambio A; Dufour JF; Marron TU; Kaseb A; Kudo M; Huang YH; Djouder N; Wolter K; Zender L; Marche PN; Decaens T; Pinato DJ; Rad R; Mertens JC; Weber A; Unger K; Meissner F; Roth S; Jilkova ZM; Claassen M; Anstee QM; Amit I; Knolle P; Becher B; Llovet JM; Heikenwalder M
Nature; 2021 Apr; 592(7854):450-456. PubMed ID: 33762733
[TBL] [Abstract][Full Text] [Related]
13. Extracellular Vesicles as Inflammatory Drivers in NAFLD.
Srinivas AN; Suresh D; Santhekadur PK; Suvarna D; Kumar DP
Front Immunol; 2020; 11():627424. PubMed ID: 33603757
[TBL] [Abstract][Full Text] [Related]
14. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH).
Nati M; Haddad D; Birkenfeld AL; Koch CA; Chavakis T; Chatzigeorgiou A
Rev Endocr Metab Disord; 2016 Mar; 17(1):29-39. PubMed ID: 26847547
[TBL] [Abstract][Full Text] [Related]
15. Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma: An emerging therapeutic strategy.
Huang C; Zhou Y; Cheng J; Guo X; Shou D; Quan Y; Chen H; Chen H; Zhou Y
Front Endocrinol (Lausanne); 2023; 14():1145392. PubMed ID: 37020586
[TBL] [Abstract][Full Text] [Related]
16. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
[TBL] [Abstract][Full Text] [Related]
17. Autophagy in nonalcoholic steatohepatitis.
Amir M; Czaja MJ
Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):159-66. PubMed ID: 21476911
[TBL] [Abstract][Full Text] [Related]
18. Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.
Radwan MM; Radwan BM; Nandipati KC; Hunter WJ; Agrawal DK
Expert Rev Clin Immunol; 2013 Aug; 9(8):727-38. PubMed ID: 23971751
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Liver Microenvironment during Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish.
Michael C; Martínez-Navarro FJ; de Oliveira S
J Vis Exp; 2021 Apr; (170):. PubMed ID: 33871465
[TBL] [Abstract][Full Text] [Related]
20. Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD).
Kragh Petersen S; Bilkei-Gorzo O; Govaere O; Härtlova A
Scand J Immunol; 2020 Nov; 92(5):e12971. PubMed ID: 32892401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
